Analysed BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) News Sources
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
24-03-2026
yahoo.com
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
17-03-2026
yahoo.com
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
12-11-2025
yahoo.com
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
30-09-2025
yahoo.com
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
11-09-2025
yahoo.com
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
04-09-2025
yahoo.com
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
12-08-2025
yahoo.com
What is the current price of BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ)?
The current price of BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) is $0.0219.
BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) since the previous trading day is $0.0012.
BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) since the previous trading day is 5.7971%.
What is the most recent average sentiment score for BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ)?
The most recent average sentiment score for BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ)?
The most recent sentiment for BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ) is .
SEC-8K** Filing Available For BIOMOTION SCIENCES-CW29 (SLXNW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.